Navigation Links
Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Date:11/16/2009

WALTHAM, Mass., Nov. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade, modest growth in the methicillin-resistant Staphylococcus aureus (MRSA) drug market will be driven in part by the uptake of three emerging agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/AstraZeneca/Takeda. The increasing prevalence of MRSA and the uptake of several premium-priced emerging therapies will drive the MRSA market to increase from $740 million in 2008 to more than $1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Methicillin-Resistant Staphylococcus Aureus finds that Theravance/Astellas's telavancin, Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca/Takeda's ceftaroline will capture more than one-third of the overall MRSA market in 2018. The two novel first-in-class anti-MRSA cephalosporins -- ceftobiprole and ceftaroline -- which are both expected to launch by 2011, will have a significant impact on the market by bringing cephalosporins to the forefront of the array of drug classes used to treat MRSA. Owing to their broad-spectrum and expanded activity against MRSA, ceftobiprole and ceftaroline are well-poised for use as first-line therapies for suspected MRSA infections in the hospital setting.

"Ceftobiprole and ceftaroline offer safe, effective, and convenient monotherapy options for simplified empiric treatment of MRSA infections in place of existing combination therapy," said Decision Resources Analyst Hemali Patel, Ph.D. "Although we anticipate robust competition between these two agents due to their similar profiles, we forecast that ceftobiprole and ceftaroline will each achieve significant commercial success and together will represent 20 percent of the overall MRSA market in 2018."

The report also finds that, in contrast to current therapies consisting largely of narrow-spectrum anti-MRSA agents, late-stage anti-MRSA emerging therapies are comprised of numerous broad-spectrum agents spanning several antibiotic drug classes. In addition, the pipeline for MRSA is also characterized by new therapies being developed in both intravenous and oral formulations (e.g., Trius Therapeutics' torezolid, Rib-X's delafloxacin, Paratek/Novartis's PTK-0796) which could address the growing need for oral MRSA therapies for both the hospital and community settings.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                  Decision Resources, Inc.
    Christopher Comfort                 Elizabeth Marshall
    781-296-2597                        781-296-2563
    ccomfort@dresources.com             emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
2. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
3. Cancer Drugs Emerging as Top Driver of Specialty Drug Spending
4. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
5. Patient-Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
8. Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
9. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
10. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
11. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2020)... NORTH PORT, Fla. (PRWEB) , ... May 15, ... ... as a traditional Chinese medicine to treat fatigue, impotence, constipation, frequent urination and ... extracted from sea cucumbers possess the ability to boost the immune system ...
(Date:5/14/2020)... ... ... A new study from the National Alliance for Caregiving (NAC) and AARP finds ... from 2015 to 2020 and now encompasses more than one in five Americans. ... compared to five years ago. As the demand for caregiving rises with an aging ...
(Date:5/14/2020)... ... 13, 2020 , ... Windsor Healthcare Management, Inc. (“Windsor Healthcare”), ... named Stacey Alexander as Chief Operating Officer (“COO”) of its organization. Ms. Alexander ... years by Tim Lehner, the outgoing COO. , Stacey’s professional life has been ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... 2020 , ... JNL Technologies Inc. , a manufacturer of safety and ... SafeHealth screening software. This tool allows companies to create an electronic screening record ... of additional paperwork management. , SafeHealth allows you to create a custom set of ...
(Date:5/16/2020)... ... May 15, 2020 , ... KUDO Inc., the ... Open Source Medical Supplies (OSMS). The organization will obtain free access to the ... spread of COVID-19. , Created as a response to the COVID-19 pandemic in ...
(Date:5/15/2020)... ... May 15, 2020 , ... Cisive, a global provider of ... its healthcare-focused background screening division, PreCheck, were both named by HR Tech Outlook ... distinguished panel comprising of CEOs, CIOs, CHROs, and analysts, along with HR Tech ...
(Date:5/15/2020)... ... May 15, 2020 , ... How do you visit your primary care provider ... offices are not set up to see their patients. Telemedicine alone doesn’t solve the ... challenging to overcome. Doctors and patients need to connect again for continuity of care. ...
(Date:5/14/2020)... ... May 14, 2020 , ... ... Nevada Community Foundation’s COVID-19 Emergency Response Fund in an effort to assist with ... , Nevada Community Foundation and Nevada COVID-19 Response, Relief, and Recovery Task Force ...
Breaking Medicine News(10 mins):